Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimetazidine for prevention of contrast-induced nephropathy during elective coronary angiography
IRCT20171004036555N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of trimetazidine in contrast-induced nephropathy (CIN) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoint: Incidence of contrast-induced nephropathy. Started Mar 2016; status: completed.
02
Drugs
trimetazidine
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on IRCT20171004036555N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171004036555N1.